Post Thumb

The Adult Brain Can Regenerate Neurons in an Unexpected Area, Says New Study

Scientists have discovered for the first time that adult mouse brains produce new cells in the amygdala, a finding that could eventually lead to better treatments for conditions like anxiety and depression, as well as a better understanding of the

Post Thumb

Two-part system turns stem cells into whatever you want

Whether using embryonic or adult stem cells, coercing these master cells to convert to the desired target cell and reproduce flawlessly is difficult. Now an international team of researchers has a two-part system that can convert the cells to the targets and then remove the remnants of that conversion, leaving only the desired DNA behind to duplicate.

Post Thumb

These 25 schools are responsible for the greatest advances in science

This item has been corrected.  Few individuals will be remembered in history for discovering a new law of nature, revolutionizing a new technology or captivating the world with their ideas. But perhaps these contributions say more about the impact of a university or college than test scores and future earnings. Which universities are most likely…

Post Thumb

New Appoach targets Cancer Stem Cells and uses tens of thousands of animal models | NextBigFuture.com

Stemcentrx, has raised $500 million and is valued at $3 billion, people familiar with its finances say, a nearly unprecedented value for a company with no revenue, facing the usual R and D obstacles, and that almost no one has heard of. Silicon Valley is used to “unicorns,” those private, usually profitless, and fast-growing tech companies worth a billion dollars or more, like Snapchat, Square, and Uber. Now the same phenomenon is spreading to biotech, where investors are throwing money at companies that promise to beat the historically low odds of drug success. The company is unusual because it’s betting on a scientific idea that’s not universally accepted-that cancer is caused not by any cell that goes rogue, but by rare and powerful cancer stem cells. Stemcentrx’s contrarian premise-that stem cells can be bad, not good-has drawn some impressive backers, including Sequoia Capital, Elon Musk, and most notably Founders Fund, the investment firm led by Peter Thiel, the Midas-touch